Find care
Spravato Reviews: What to Know Before Booking
Spravato reviews are most useful when they separate the medicine from the clinic providing it. Spravato is FDA-approved esketamine nasal spray for specific adult depression indications, delivered in a certified healthcare setting. Our view: its regulated treatment process is a clear advantage for someone seeking an approved option, while repeated clinic visits, monitoring, transportation and insurance approval can be substantial obstacles.
This is a review of published prescribing information and access requirements. We have not taken Spravato, tested clinics or collected a patient satisfaction score. A clinician must assess whether it fits your history.
Spravato at a glance
| Decision point | What it means for you |
|---|---|
| Medicine | Esketamine nasal spray; distinct from compounded ketamine |
| Approved depression uses | Adult treatment-resistant depression, alone or with an oral antidepressant; depressive symptoms in adults with major depressive disorder and suicidal thoughts or actions, with an oral antidepressant |
| Where you receive it | A healthcare setting certified in the Spravato REMS program |
| Monitoring | At least two hours after administration; discharge is a clinical decision |
| Ride home | Someone must drive you home; the label restricts driving until the next day after restful sleep |
| Price | Your total depends on coverage, medicine, clinic charges and assistance eligibility |
| Main limitation | Approval does not establish that it will work for you or make treatment risk-free |
Source: FDA Medication Guide, revised September 2026.
If you want a supervised clinic option, start with the manufacturer's information and ask a participating clinic about screening and benefits verification. A provider listing is a starting point, not our endorsement of that clinic.
Visit the official Spravato sitespravato.com
What Spravato is approved to treat
The indication depends on the diagnosis. For treatment-resistant depression in adults, Spravato may be used with or without an oral antidepressant. Its other depression indication requires an oral antidepressant. The medicine is not approved as a take-home nasal spray or an anesthetic.
The label also says it has not been established to prevent suicide or reduce suicidal thoughts or actions. It does not replace hospitalization when a healthcare professional determines that hospitalization is needed. These limits matter when reading dramatic stories about rapid relief. See the current FDA guide rather than relying on older articles that say an oral antidepressant is always required.
For the broader distinction, read Spravato vs ketamine.
What the clinical evidence shows
The current prescribing information describes a randomized, double-blind, placebo-controlled monotherapy trial in adults with treatment-resistant depression. At day 28, the two studied Spravato groups improved more than placebo on the Montgomery–Åsberg Depression Rating Scale, a clinician-rated symptom measure. The adjusted between-group differences were 5.1 and 6.8 points in Spravato's favor. This was a group comparison, not a percentage of people cured or a prediction of your response.
The label also describes maintenance research in people who first achieved a stable response or remission. That selected population matters when interpreting continued-treatment results. Source: prescribing information, Clinical Studies section. Ask the clinician how evidence and follow-up apply to your situation.
Where Spravato has a practical advantage
Its approved labeling and required healthcare setting make the care process easier to identify. You can ask a clinic how it follows the program, what it monitors and who is responsible for discharge. That does not remove risk, but it gives you concrete requirements to verify.
It also creates a different insurance conversation from a cash-pay compounded ketamine program. A plan can still deny a request or require prior authorization. Ask for a benefits check for the exact clinic and treatment before making work or travel arrangements. Our insurance guide explains why the drug bill and the visit bill may need separate questions.
The main drawbacks to plan around
The visit commitment may be the deciding factor even if the medicine is clinically appropriate. Monitoring is only part of the time: travel, check-in and the ride home add to the burden. A person who can attend one appointment may still struggle to sustain repeated appointments.
Cost can also be unclear until the clinic and insurer complete a check. A low medicine copay is not automatically the full visit price. Observation, evaluations, other care and transport need their own line items. Use the Spravato cost guide to request a complete estimate.
Finally, an unpleasant or difficult session is not proof that treatment is working. Ask the clinician how they respond to side effects and how they decide whether to continue, change or stop a course. You should not need to accept a promise of transformation to get a clear answer.
Risks that a balanced review should include
The FDA Medication Guide describes serious risks including sedation, dissociation, respiratory depression, misuse and increased blood pressure. The screening discussion also needs to cover medical history, other medicines, pregnancy or breastfeeding and relevant contraindications. Review the FDA guide with the prescribing team.
Tell the clinic about all medicines and supplements. Do not stop an existing medicine to qualify for a program unless your own clinician directs the change. If you need urgent psychiatric care, use urgent or emergency services rather than waiting for a commercial consultation.
How to read patient reviews without being misled
A patient story can tell you what a visit felt like. It cannot tell you your odds of benefit. Separate three questions as you read:
- Medicine experience: Was the person describing symptom change, side effects or both? Over what period?
- Clinic experience: Were scheduling, staff communication, billing and discharge handled well?
- Treatment context: Was this actually Spravato, or was it a compounded ketamine treatment called “ketamine therapy”?
Ask whether a review was solicited, incentivized or published by the provider. A dramatic improvement story and a bad billing story can both be sincere while describing very different aspects of care. We do not combine these stories into a clinical success percentage.
Questions to ask the clinic before you commit
Get these answers in writing where possible:
- Are you certified in the Spravato REMS program, and who will prescribe and monitor my care?
- What diagnosis and treatment records do you need for clinical screening and prior authorization?
- What would my first month require in visits, transport and time away from work?
- Does the estimate include medicine, evaluation and observation? What might generate a separate bill?
- If coverage is denied, do I owe anything, and what is your cancellation policy?
- How will you measure benefit and adverse effects, and when will we reassess the plan?
- Who do I contact between visits, and what situations require urgent care?
A clear clinic should be able to discuss these without promising a particular outcome.
When another option may fit your circumstances better
If frequent monitored visits are the barrier, ask your clinician about the full set of alternatives. TMS, standard depression care and other specialist treatments have different practical requirements. At-home ketamine has a different approval and monitoring profile; it should not be treated as the same treatment delivered more conveniently.
If your main question is price, compare the total cost of ketamine treatment routes. If your main question is the healthcare setting, compare Spravato and other ketamine options before contacting a provider.
How we checked this review
We checked FDA labeling and manufacturer access information on November 17, 2026. This review evaluates the documented treatment and booking decision; it does not rate individual clinics or replace a medical assessment. Treatment choices and coverage must be confirmed with the clinician and plan involved.